View all data FOR FREE!
Create an account today, no credit card required.
| Issue Type | XXXX |
|---|---|
| Country | United States |
| Industry | XXXX |
| Region | XXXX |
| Maturity Date | 2028-02-20 |
| Par Value | 2000 |
| Callable | XXXX |
| Next Call Date | XXXX |
| Call Type | XXXX |
| Call Price (%) | XXXX |
| Series | XXXX |
| Class | XXXX |
| Maturity Structure | XXXX |
| Amount Outstanding (mil) | 43.84 |
| Coupon | 3.9 |
|---|---|
| Coupon Type | XXXX |
| Coupon Frequency | XXXX |
| First Coupon Date | XXXX |
| Last Coupon Date | XXXX |
| Sinking Fund | XXXX |
|---|---|
| Security | XXXX |
| Subordination | XXXX |
| Debt Type | XXXX |
| Issue Date | XXXX |
|---|---|
| Dated Date | XXXX |
| Issue Size (mil) | 1500 |
| Min. Piece | XXXX |
| Min. Increment | XXXX |
This Celgene Corp. corporate note has a 3.90% fixed rate coupon paid on a semi-annual basis. It was issued on February 20, 2018 with an issue size of 1500.00 million USD and matures on February 20, 2028 with a last coupon date of August 20, 2027. |
Celgene Corp., founded in 1986 and headquartered in Summit, New Jersey, is a biopharmaceutical company dedicated to developing innovative therapies for cancer and inflammatory disorders. The company's prominent products include Revlimid, a treatment for multiple myeloma, and Pomalyst, used for relapsed or refractory multiple myeloma, which have positioned Celgene as a leader in the biotechnology sector.